| Structures of the Omicron spike trimer with ACE2 and an anti-Omicron antibody W Yin, Y Xu, P Xu, X Cao, C Wu, C Gu, X He, X Wang, S Huang, Q Yuan, ... Science 375 (6584), 1048-1053, 2022 | 267 | 2022 |
| Cryo-EM structure of an activated VIP1 receptor-G protein complex revealed by a NanoBiT tethering strategy J Duan, D Shen, XE Zhou, P Bi, Q Liu, Y Tan, Y Zhuang, H Zhang, P Xu, ... Nature communications 11 (1), 1-10, 2020 | 171 | 2020 |
| Molecular recognition of morphine and fentanyl by the human μ-opioid receptor Y Zhuang, Y Wang, B He, X He, XE Zhou, S Guo, Q Rao, J Yang, J Liu, ... Cell 185 (23), 4361-4375. e19, 2022 | 163 | 2022 |
| Activation pathway of a G protein-coupled receptor uncovers conformational intermediates as targets for allosteric drug design S Lu, X He, Z Yang, Z Chai, S Zhou, J Wang, AU Rehman, D Ni, J Pu, ... Nature communications 12 (1), 4721, 2021 | 161 | 2021 |
| Allosteric modulator discovery: from serendipity to structure-based design S Lu, X He, D Ni, J Zhang Journal of medicinal chemistry 62 (14), 6405-6421, 2019 | 152 | 2019 |
| Discovery of cryptic allosteric sites using reversed allosteric communication by a combined computational and experimental strategy D Ni, J Wei, X He, AU Rehman, X Li, Y Qiu, J Pu, S Lu, J Zhang Chemical science 12 (1), 464-476, 2021 | 106 | 2021 |
| Structures of full-length glycoprotein hormone receptor signalling complexes J Duan, P Xu, X Cheng, C Mao, T Croll, X He, J Shi, X Luan, W Yin, E You, ... Nature 598 (7882), 688-692, 2021 | 84 | 2021 |
| Deactivation pathway of Ras GTPase underlies conformational substates as targets for drug design S Lu, D Ni, C Wang, X He, H Lin, Z Wang, J Zhang Acs Catalysis 9 (8), 7188-7196, 2019 | 83 | 2019 |
| AlphaFold2 versus experimental structures: evaluation on G protein-coupled receptors X He, C You, H Jiang, Y Jiang, HE Xu, X Cheng Acta Pharmacologica Sinica 44 (1), 1-7, 2023 | 81 | 2023 |
| Emergence of allosteric drug-resistance mutations: new challenges for allosteric drug discovery S Lu, Y Qiu, D Ni, X He, J Pu, J Zhang Drug discovery today 25 (1), 177-184, 2020 | 80 | 2020 |
| Ligand recognition and G-protein coupling selectivity of cholecystokinin A receptor Q Liu, D Yang, Y Zhuang, TI Croll, X Cai, A Dai, X He, J Duan, W Yin, ... Nature chemical biology 17 (12), 1238-1244, 2021 | 78 | 2021 |
| Drugging K-RasG12C through covalent inhibitors: mission possible? D Ni, X Li, X He, H Zhang, J Zhang, S Lu Pharmacology & therapeutics 202, 1-17, 2019 | 78 | 2019 |
| Mechanism of allosteric activation of SIRT6 revealed by the action of rationally designed activators S Lu, Y Chen, J Wei, M Zhao, D Ni, X He, J Zhang Acta Pharmaceutica Sinica B 11 (5), 1355-1361, 2021 | 70 | 2021 |
| Unraveling allosteric landscapes of allosterome with ASD X Liu, S Lu, K Song, Q Shen, D Ni, Q Li, X He, H Zhang, Q Wang, Y Chen, ... Nucleic acids research 48 (D1), D394-D401, 2020 | 70 | 2020 |
| Molecular recognition of an acyl-peptide hormone and activation of ghrelin receptor Y Wang, S Guo, Y Zhuang, Y Yun, P Xu, X He, J Guo, W Yin, HE Xu, X Xie, ... Nature Communications 12 (1), 5064, 2021 | 61 | 2021 |
| Structural insights into the SARS-CoV-2 Omicron RBD-ACE2 interaction J Lan, X He, Y Ren, Z Wang, H Zhou, S Fan, C Zhu, D Liu, B Shao, TY Liu, ... Cell research 32 (6), 593-595, 2022 | 59 | 2022 |
| GPCR activation and GRK2 assembly by a biased intracellular agonist J Duan, H Liu, F Zhao, Q Yuan, Y Ji, X Cai, X He, X Li, J Li, K Wu, T Gao, ... Nature 620 (7974), 676-681, 2023 | 58 | 2023 |
| Hormone-and antibody-mediated activation of the thyrotropin receptor J Duan, P Xu, X Luan, Y Ji, X He, N Song, Q Yuan, Y Jin, X Cheng, ... Nature 609 (7928), 854-859, 2022 | 49 | 2022 |
| Structural basis of leukotriene B4 receptor 1 activation N Wang, X He, J Zhao, H Jiang, X Cheng, Y Xia, H Eric Xu, Y He Nature communications 13 (1), 1156, 2022 | 47 | 2022 |
| Molecular basis of ligand recognition and activation of human V2 vasopressin receptor F Zhou, C Ye, X Ma, W Yin, TI Croll, Q Zhou, X He, X Zhang, D Yang, ... Cell research 31 (8), 929-931, 2021 | 43 | 2021 |
H Eric Xu (徐华强), ProfessorShanghai Institute of Materia Medica, CAS; Tsinghua; Duke; UTSW; MIT; VARI/GlaxoWellcome/GSKVerificeret mail på simm.ac.cn